Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study

BACKGROUND: ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM’s primary aim was to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Margolese, Howard C., Boucher, Matthieu, Therrien, Francois, Clerzius, Guerline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733174/
https://www.ncbi.nlm.nih.gov/pubmed/36482352
http://dx.doi.org/10.1186/s12888-022-04397-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733174/
https://www.ncbi.nlm.nih.gov/pubmed/36482352
http://dx.doi.org/10.1186/s12888-022-04397-x

Ejemplares similares